

## **PEOPLE**

Ronald Abrahams has been promoted from COO to acting CEO of Ergo Science (Boston, MA) replacing Warren Huff who has resigned to pursue other interests.

Progenitor, Inc. (Columbus, OH), a majority-owned unit of Interneuron Pharmaceuticals, has named Mark Bagnall chief financial officer and vice president. Bagnall was most recently vice president of finance and chief financial officer at Somatix Therapy Corp.

Samuel C. Fleming and Paul A. Friedman have been appointed to the board of directors of ImmuLogic (Waltham, MA), bringing the number of board members to eight. In addition, Alan W. Tuck has joined the company as chief strategic officer. Mr. Fleming is chairman and CEO of Decision Resources, Inc., and Dr. Friedman is president of Dupont Merck Research Labs.

McKesson Corp. (San Francisco, CA) has named Richard H. Hawkins to the additional position of chief financial officer. Hawkins has been a corporate vice president since 1993 and controller since 1990. Hawkins replaces Kevin B. Ferrell, who resigned to join Bankers Trust Company.

Craig N. Hess has been appointed to the newly created position of senior vice president, operations of Dyax Corporation's (Cambridge, MA) separations division. Prviously, he served as vice president of engineering at Polymer Design Corp.

Roberts Pharmaceutical Corporation (Eatontown, NJ) has announced the election of Zola P. Horovitz to its board of directors. The elec-

tion of Dr. Horovitz fills the vacancy created by the recent passing of W. Robert Fowler, a longstanding member of the Roberts board. Dr. Horovitz retired from Bristol-Myers Squibb in 1994 after serving as vice president of business development and planning and, prior to that, as vice president of licensing.

Audrey D. Keane has joined Genset (La Jolla, CA) as vice president, business development. Ms. Keane was previously vice president of business development at Sequana Therapeutics.

Thomas F. Keller has been elected to the board of directors of Biogen (Cambridge, MA). Dr. Keller is R.J. Reynolds professor of business administration at Duke University, and former dean of the Fuqua School of Business at Duke.

Everen Securities (Chicago) has named Jeffrey Kraws to the new positions of managing director and senior equity analyst, pharmaceutical industry. Kraws was senior US pharmaceutical analyst at Asea Brown Boveri, a Swedish-Swiss conglomerate, as well as managing director and president of Asea Brown's US investment brokerage division.

Variagenics, Inc. has announced the appointment of Fred D. Ledley to the position of president and chief operating officer and chairman. Dr. Ledley joins the company from GeneMedicine, Inc., where he was vice president, medicine and scientific founder.

Max Link has joined the board of directors of Paradigm Biosciences (Salt Lake City, UT). Dr. Link was previously CEO and chairman of the board of Sandoz Pharma.

David J. Main has been appointed to the new position of vice president, corporate development at Inex Pharmaceuticals (Vancouver, Canada). Mr. Main was previously a vice president at QLT PhotoTherapeutics.

Steven Mayer has joined Human Genome Sciences (Rockville, MD) as senior vice president and CFO. Previously, Mayer was CFO at GenVec (Rockville, MD).

Stephen Miller has been promoted from vice president and chief medical officer to senior vice president and chief scientific and medical officer of Atlantic Pharmaceuticals (Half Moon Bay, CA).

Interferon Sciences (New Brunswick, NJ) has announced the appointment of Magnus Precht as executive vice president, sales and marketing, and James R. Knill as vice president of medical affairs. Precht joins the company from Pharmacia, where he was vice president and general manager of its US peptide hormones division since 1990. Dr. Knill was previously vice president of medical affairs for Cytogen Corp.

Pharmos Corp. (Alachua, FL) has named Fredric D. Price a director, replacing William C. Hulley, who resigned. Price is president, chief executive, and a director of Applied Microbiology Inc.

Technical Chemicals and Products (Fort Lauderdale, FL) has announced that Clayton L. Rautbord will be joining its board of directors, replacing Elias Amador. Mr. Rautbord was formerly the president and CEO of APECO.



For use in diagnostics and pharmaceutical packaging where leakage and product loss are not acceptable.

■ Superior cap seal system ■ 4 ml to 250 ml capacity ■ Small and large quantities.

Polyvials are manufactured exclusively from virgin HDPE using modern precision production methods and strict quality control. They are available in natural or black pigmented. Black Polyvials are absolutely light tight, for packaging light sensitive materials with confidence.

ZINSSER ANALYTIC GMBH Eschborner Landstraße 135 D-60489 Frankfurt/Germany Telephone (069)789106-0 Telefax (069)789106-80

